[关键词]
[摘要]
目的 观察胸腺肽联合GP方案治疗非小细胞肺癌的疗效及对免疫功能和血管内皮生长因子(VEGF)表达水平的影响。方法 选取2017年4月-2019年6月期间安康市中医医院收治的80名非小细胞肺癌患者作为研究对象,采用随机数字表法分为对照组和观察组,每组40例。对照组在第1天、第8天静脉滴注注射用盐酸吉西他滨,1.0 g/m2,1次/d,第1~3天静脉滴注注射用顺铂,25 mg/m2,1次/d。观察组在对照组的基础上口服胸腺肽肠溶片,15 mg,2次/d。21 d为1个周期,两组均治疗2个周期。观察两组患者的近期临床疗效,比较两组患者的KPS评分、免疫功能指标和血管内皮生长因子(VEGF)水平。结果 治疗后,对照组客观有效率(ORR)为47.50%,观察组为57.50%,两组差异无统计学差异。治疗后,观察组患者KPS评分优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的CD4+、CD8+、CD4+/CD8+及NK细胞的比例与治疗前有统计学差异(P<0.05);治疗后,观察组患者CD4+、CD8+、CD4+/CD8+及NK细胞比例均优于对照组,差异具有统计学(P<0.05)。治疗后,两组VEGF水平均显著降低(P<0.05);与对照组相比,观察组下降更为显著(P<0.05)。结论 胸腺肽肠溶片联合GP方案用于非小细胞肺癌的临床治疗,提高了患者的生存质量和免疫功能,降低了血清VEGF水平。
[Key word]
[Abstract]
Objective To observe the effect of thymopdypeptide combined with GP regimen on non-small cell lung cancer and its effect on immune function and expression level of VEGF. Methods A total of 80 patients with non small cell lung cancer in the Ankang Hospital of Traditional Chinese Medicine from April 2017 to June 2019 were selected as research objects, and randomly divided into the control group and the observation group, with 40 cases in each group. Patients in the control group were iv administerted with Gemcitabine Hydrochloride Injection for D1 and D8, 1.0 g/m2, once daily, and iv administerted with Cisplatin for Injection from D1 to D3, 25 mg/m2, once daily. Patients in observation group were po administered with Thymopdypeptide EntericCoated Tablets on the basis of control group, 15 mg, twice daily. 21 d was 1 cycle, and both groups were treated for 2 cycles. The short-term clinical efficacy in two groups was observed, and the KPS score, immune function index, and VEGF in two groups were compared. Results After treatment, the objective effective rate (ORR) was 47.50% in the control group, and 57.50% in the observation group, there was no statistical difference between the two groups. After treatment, the KPS score in the observation group was better than that in the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment, the proportions of CD4+, CD8+, CD4+/CD8+, and NK cells in two groups were statistically different from those before treatment (P<0.05). After treatment, the proportions of CD4+, CD8+, CD4+/CD8+ and NK cells in the observation group were better than those in the control group, with statistically significant differences (P<0.05). After treatment, VEGF levels in two groups were significantly reduced (P<0.05). Compared with the control group, the decrease was more significant in the observation group (P<0.05). Conclusion Thymopdypeptide Enteric-Coated Tablets combined with GP regimen in treatment of non-small cell lung cancer, can improved the quality of life and immune function of patients, and reduced the serum VEGF level.
[中图分类号]
R979.1
[基金项目]
陕西省科技惠民计划项目(2016HM-09)